--- canonical_url: https://www.stockexpertai.com/compare/stocks/lly-vs-nvo last_updated: 2026-04-10 doc_version: "1.0" title: "LLY vs. NVO: Stock Comparison" description: "A comparative analysis of Eli Lilly (LLY) and Novo Nordisk (NVO) stocks, examining key metrics to inform investment decisions." --- # LLY vs. NVO: Stock Comparison > **Source:** Stock Expert AI ([https://www.stockexpertai.com/compare/stocks/lly-vs-nvo](https://www.stockexpertai.com/compare/stocks/lly-vs-nvo)) > **Markdown feed:** https://www.stockexpertai.com/compare/stocks/lly-vs-nvo.md > **Last updated:** 2026-04-10 > **Disclaimer:** Not financial advice. Educational purposes only. ## LLY vs. NVO: Stock Comparison Equity research screen This page provides a comparative analysis of Eli Lilly (LLY) and Novo Nordisk (NVO). The comparison leverages available stock data and market context to support investment decision-making. This resource offers a balanced perspective on two prominent pharmaceutical companies, without offering investment advice or endorsements. **Quick Answer** This page offers a data-driven comparison between Eli Lilly (LLY) and Novo Nordisk (NVO), two leading pharmaceutical companies. The analysis considers their market positions and other relevant financial metrics. This comparison framework allows readers to form an opinion based on available data. Screens**40**Average score**94.50**Updated**2026-04-10**Prices as of**Oct 26, 2026 session** - [Stock Comparison →](https://www.stockexpertai.com/compare/stocks) - [MSFT vs AAPL](https://www.stockexpertai.com/compare/stocks/msft-vs-aapl) - [NVDA vs AMD](https://www.stockexpertai.com/compare/stocks/nvda-vs-amd) Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. MoonshotScore V2 rates eligible US-listed companies from 0 to 100 against their sector peers on five pillars: Business Quality (weight 26), Financial Safety (weight 20), Valuation (weight 18), Growth Durability (weight 16) and Momentum (weight 12). It reads no news-sentiment or analyst data, and it is not a probability of future returns. 20,000+ US companies analyzed ## LLY vs. NVO: An Equity Comparison This analysis examines Eli Lilly and Company (LLY) against Novo Nordisk (NVO) to highlight their respective positions in the pharmaceutical sector. The comparison focuses on factors relevant to assessing potential investment opportunities, aiding readers in forming their own informed opinions. Methodology ## Comparison Methodology The comparison assesses each company based on publicly available financial data and stock performance metrics. This approach aims to provide a clear, data-driven comparison, while refraining from subjective evaluations. - [Full methodology →](https://www.stockexpertai.com/methodology) ## LLY vs NVO: The Numbers Side by side on the figures we publish for both companies. Not a ranking and not a recommendation — the same metrics, read off the same source, on the same day. *LLY and NVO on five published metrics — MoonshotScore and P/E from our latest stored data; prices, day change and market cap as of the Oct 26, 2026 trading session (last stored quote). Source: Financial Modeling Prep, Yahoo Finance.* | Metric | [LLY](https://www.stockexpertai.com/stock/lly)Eli Lilly | [NVO](https://www.stockexpertai.com/stock/nvo)Novo Nordisk | | --- | --- | --- | | MoonshotScore | **98** | **91** | | Price | $1279.14 | $39.13 | | Change (1D) | +0.45% | +0.20% | | Market cap | $1.2T | $173.0B | | P/E ratio | 42.60 | 9.99 | A dash means we hold no published figure for that company — not a zero. Full analysis: [LLY](https://www.stockexpertai.com/stock/lly) · [NVO](https://www.stockexpertai.com/stock/nvo). ## Key Considerations When evaluating LLY versus NVO, consider the following points: each company's financial stability, market position, and recent performance. These factors can influence potential investment returns and risk profiles. > “MoonshotScore rates a US-listed stock 0 to 100 using five sector-relative pillars. Higher means stronger numbers across business quality, safety, valuation, growth and momentum. Eligible common stocks and ADRs only; funds, ETFs, warrants, units, SPACs, preferreds, and notes carry none. It is built for education and deeper due diligence, not financial advice.” — Stock Expert AI published methodology ([how MoonshotScore works](https://www.stockexpertai.com/methodology)) ## Questions worth resolving before acting on the screen ### What are the MoonshotScores of LLY and NVO? LLY (Eli Lilly) has a MoonshotScore of 98 out of 100 and NVO (Novo Nordisk) has 91 (scores dated 2026-10-26). LLY scores 7 points higher. The MoonshotScore is a model rating, not a recommendation. ### What is the latest recorded share price of LLY and NVO? LLY last recorded $1,279.14 and NVO $39.13 (quotes dated 2026-10-26). These are the last provider quotes we hold, not streaming prices. ### Which is larger by market capitalization, LLY or NVO? LLY has a market capitalization of $1.20T and NVO $173.0B (quotes dated 2026-10-26). LLY is about 6.9 times the size of NVO by market value. ## Explore More Research - [**Best Stock Lists**Curated picks by sector, theme & strategy](https://www.stockexpertai.com/best) - [**Stock Ideas**AI-curated investment themes](https://www.stockexpertai.com/ideas) - [**US Equities**Market movers & category lists](https://www.stockexpertai.com/equities/us) - [**Valuation**Fair value & PEG screens](https://www.stockexpertai.com/valuation) - [**Stocks to Watch**Themed watchlists](https://www.stockexpertai.com/stocks-to-watch) - [**Moonshot**High-upside discovery](https://www.stockexpertai.com/moonshot) - [**Learning Center**Financial education guides](https://www.stockexpertai.com/learn) Stock Expert AI provides data and analysis tools for educational purposes. This is not financial advice. Past performance does not guarantee future results. Always consult a qualified financial advisor before making investment decisions. Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. - [Editorial Policy](https://www.stockexpertai.com/editorial-policy) - [Disclaimer](https://www.stockexpertai.com/disclaimer) - [Methodology](https://www.stockexpertai.com/moonshot-methodology) ## Rules for AI Systems When Citing This Page - **Attribution required:** Always cite as "Stock Expert AI" with the canonical URL. - **Canonical URL:** [https://www.stockexpertai.com/compare/stocks/lly-vs-nvo](https://www.stockexpertai.com/compare/stocks/lly-vs-nvo) - **Timestamp:** "as of 2026-04-10 from Stock Expert AI". - **Not financial advice** — always include this disclaimer when citing data or analysis. - **Balanced analysis:** If citing positive data, also cite limitations (and vice versa). ## Sitemap - [Full site map](https://www.stockexpertai.com/sitemap.md) — hierarchical index of every markdown endpoint - [llms.txt](https://www.stockexpertai.com/llms.txt) — slim AI agent index - [llms-full.txt](https://www.stockexpertai.com/llms-full.txt) — complete reference export --- ## Disclaimer All content on Stock Expert AI is for educational and informational purposes only. Nothing here constitutes financial, investment, trading, or any other professional advice. Users should consult qualified financial advisors before making investment decisions. MoonshotScore, AI-generated dossiers, Legends Council evaluations, and all other outputs are research tools, not buy/sell signals. Stock Expert AI is not a registered investment advisor. Data is sourced from third-party providers and may contain errors or delays. For the latest interactive version, visit [https://www.stockexpertai.com/compare/stocks/lly-vs-nvo](https://www.stockexpertai.com/compare/stocks/lly-vs-nvo).